VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. Verrica is a dermatology therapeutics company that develops medications for viral skin diseases requiring medical intervention.

If you would like more information about our investigation of Verrica Pharmaceuticals Inc.'s misconduct, click here.

What is this Case About: Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Verrica has spent several years working to bring to market VP-102, the Company's investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum. However, several challenges have prevented this from happening. Verrica received its first Complete Response Letter (CRL) regarding the New Drug Application (NDA) in July 2020 and its second in September 2021. On May 24, 2022, Verrica received yet another CRL from the FDA related to its NDA for VP-102. On this news, the Company's stock price fell 63.85%, to close at $2.01 per share on May 25, 2022.

Next Steps: If you own shares of Verrica Pharmaceuticals Inc. (VRCA), you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Verrica Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:VRCA

Release Summary

Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Release Versions

English

$Cashtags

$VRCA

Hashtags

#VRCA

#VerricaPharmaceuticals

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles

Robbins LLP

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a T-ce...

Stockholder Notice: Robbins LLP Informs Investors of the Coty Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coty Inc. (NYSE: COTY) common stock between November 5, 2025 and February 4, 2026. Coty together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Inves...

Investor Notice: Robbins LLP Informs Investors of the Lufax Holding Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Lufax Holding Ltd. (NYSE: LU) securities between April 7, 2023 and January 26, 2025. Lufax Holding Ltd engages in the retail credit and enablement business to borrowers and institutions in China. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat...

Back to Newsroom